Esperion tanks on warning that the road to an FDA decision could be much, much longer than they thought
Last summer Esperion ($ESPR) triggered a big rally for its shares when CEO Tim Mayleben told investors and analysts that the FDA wouldn’t require a longterm cardio outcomes study before issuing a marketing decision on its cholesterol-lowering drug.
Today, that one-time certainty became distinctly cloudy as Mayleben says the FDA may in fact do what some investors had feared — put any marketing decision well down the road.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.